Irit Avni-Biron

BACKGROUND: Biological treatment in inflammatory bowel disease (IBD) patients is currently hampered by high non-response rates. To enhance personalized medicine and predict response to biological therapeutics such as vedolizumab, the working mechanism should be elucidated…

BACKGROUND: Early detection of inflammatory flares and corresponding treatment adjustment were shown to improve inflammatory bowel disease (IBD) patient care. Current episodic inflammatory biomarker testing allows limited monitoring and is associated with suboptimal compliance…